Last reviewed · How we verify
placebo then opana then darvocet
placebo then opana then darvocet is a Opioid analgesic Small molecule drug developed by University of Rochester. It is currently FDA-approved for Moderate to severe pain (trial comparison). Also known as: opana: oxymorphone HCL, darvocet: propoxyphene/acetaminophen, placebo: inactive drug.
This is a clinical trial comparing placebo to two opioid analgesics (oxymorphone and propoxyphene) for pain relief.
This is a clinical trial comparing placebo to two opioid analgesics (oxymorphone and propoxyphene) for pain relief. Used for Moderate to severe pain (trial comparison).
At a glance
| Generic name | placebo then opana then darvocet |
|---|---|
| Also known as | opana: oxymorphone HCL, darvocet: propoxyphene/acetaminophen, placebo: inactive drug |
| Sponsor | University of Rochester |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
The trial sequentially administers placebo, then Opana (oxymorphone, a semi-synthetic mu-opioid agonist), then Darvocet (propoxyphene/acetaminophen, a synthetic opioid), to evaluate their relative efficacy and safety. Both active drugs work by binding mu-opioid receptors in the central nervous system to reduce pain perception.
Approved indications
- Moderate to severe pain (trial comparison)
Common side effects
- Nausea
- Constipation
- Dizziness
- Drowsiness
- Respiratory depression
Key clinical trials
- Lumbar Stenosis Outcomes Research II (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo then opana then darvocet CI brief — competitive landscape report
- placebo then opana then darvocet updates RSS · CI watch RSS
- University of Rochester portfolio CI
Frequently asked questions about placebo then opana then darvocet
What is placebo then opana then darvocet?
How does placebo then opana then darvocet work?
What is placebo then opana then darvocet used for?
Who makes placebo then opana then darvocet?
Is placebo then opana then darvocet also known as anything else?
What drug class is placebo then opana then darvocet in?
What development phase is placebo then opana then darvocet in?
What are the side effects of placebo then opana then darvocet?
What does placebo then opana then darvocet target?
Related
- Drug class: All Opioid analgesic drugs
- Target: All drugs targeting Mu-opioid receptor
- Manufacturer: University of Rochester — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Moderate to severe pain (trial comparison)
- Also known as: opana: oxymorphone HCL, darvocet: propoxyphene/acetaminophen, placebo: inactive drug
- Compare: placebo then opana then darvocet vs similar drugs
- Pricing: placebo then opana then darvocet cost, discount & access